Ardena is pleased to announce that a Commercial Agency Agreement for Taiwan (ROC) has been signed with the company Medi-Point North Healthcare Co., Ltd.
Medi-Point North Healthcare is covering all key stages from drug discovery over regulatory approval to commercialization and is well up to date with Taiwan FDA latest regulations and guidelines.
The company will develop the market in Taiwan (ROC) for the entire Ardena services platform.
The Taiwanese Stock Exchange list includes around 125 public biotech companies.
The biotech market represents an important business opportunity for Ardena in addition to the 220 privately owned Taiwanese pharmaceutical companies.
The commercial agency shall commence on December 01st, 2020.